1-3 of 3
Noriyoshi Iriyama
Close
Sort by
Journal Articles

Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study

Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki
Journal: Blood Advances
Blood Adv bloodadvances.2024012655.
https://doi.org/10.1182/bloodadvances.2024012655
Published: 2024
Includes: Supplemental data
Journal Articles

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11

Clinical Trials & Observations
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood Advances
Blood Adv (2020) 4 (1): 66–75.
https://doi.org/10.1182/bloodadvances.2019000709
Published: 2020
Includes: Supplemental data
Journal Articles

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation

Clinical Trials & Observations
Koichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, Noriko Usui, Chiaki Nakaseko, Hiroyuki Fujita, Shin Fujisawa, Toru Sakura, Hirokazu Okumura, Noriyoshi Iriyama, Nobuhiko Emi, Katsumichi Fujimaki, Sumihisa Honda, Yasushi Miyazaki, Tomoki Naoe
Journal: Blood Advances
Blood Adv (2019) 3 (3): 312–319.
https://doi.org/10.1182/bloodadvances.2018025981
Published: 2019
Includes: Supplemental data